News

Merit Medical Marks Milestone in Breast Cancer Treatment Innovation

Merit Medical Marks Milestone in Breast Cancer Treatment Innovation

Milestone Achievement in Breast Cancer Treatment

Merit Medical Systems, Inc. (NASDAQ: MMSI), renowned for its innovative healthcare technology solutions, has achieved a remarkable milestone: the SCOUT® Radar Localization system has successfully treated 750,000 patients globally. This achievement is especially significant during Breast Cancer Awareness Month, a period dedicated to raising awareness about breast cancer, promoting early detection, and exploring quality treatment options available to individuals.

Understanding the Impact of Breast Cancer

This year, it’s anticipated that more than 300,000 new cases of invasive breast cancer will be diagnosed in women, highlighting the ongoing need for effective solutions. As a leader in wire-free non-radioactive localization technology, Merit Medical is committed to alleviating the difficult burdens that cancer imposes on patients and their families. The SCOUT technology allows healthcare providers to accurately target and remove cancerous tissue, resulting in procedures that are less traumatic for patients.

How SCOUT Works

SCOUT employs an innovative reflector, about the size of a grain of rice, which facilitates surgery with an accuracy of +/- 1 mm. This precision can lead to better surgical outcomes and patient experiences. The system is versatile, supporting various treatment needs, whether for breast tissue or lymph nodes, and is useful both prior to and following neoadjuvant chemotherapy. SCOUT is also effective at the time of biopsy, and its bracketing technique aids in targeting larger or multifocal tumors for breast-conserving therapies.

Expanding the Horizons of Surgical Localization

In its continuous quest to improve surgical localization, Merit Medical introduced SCOUT MD™, a next-generation system that offers four unique reflector shapes equipped with distinct radar signals. This innovation enhances the mapping of tumor margins and allows for the localization of multiple lesions or lymph nodes, further improving the efficacy of treatment.

Recognized for Excellence

The SCOUT technology has gained international recognition, being cited in over 100 clinical publications, which involve nearly 8,500 patients. The system has been adopted across 50 countries, with upwards of 500 procedures performed daily, resulting in an impressive 10,000 cases anticipated each month. Over 1,100 facilities worldwide opt for SCOUT as their preferred wire-free localization method, demonstrating the trust placed in its effectiveness by medical professionals.

Commitment to Patient Care and Community Support

“We are thrilled to witness the positive influence SCOUT has had on countless patients, particularly during Breast Cancer Awareness Month,” expressed Fred Lampropoulos, Chairman and CEO of Merit Medical. “Our support for individuals living with breast cancer goes beyond this month; through innovations like SCOUT, we strive to aid more patients in their journey to becoming cancer-free.”

About Merit Medical

Founded in 1987, Merit Medical Systems, Inc. focuses on developing, manufacturing, and distributing proprietary medical devices intended for interventional and diagnostic procedures in various specialties, including cardiology, radiology, oncology, and endoscopy. With a robust clinical support team and sales force comprising over 800 professionals, Merit serves healthcare providers worldwide. The company is proud to employ approximately 7,300 individuals across the globe, dedicated to advancing healthcare solutions.

Frequently Asked Questions

What is the SCOUT Radar Localization technology?

The SCOUT technology is a wire-free, non-radioactive localization system designed to assist surgeons in accurately targeting and removing breast cancer tissue.

How many patients have been treated with SCOUT?

SCOUT has treated over 750,000 patients around the world, marking a significant milestone in its usage.

Where has SCOUT technology been adopted?

SCOUT technology has been utilized in more than 50 countries and is the preferred choice for over 1,100 medical facilities globally.

What is the next-generation SCOUT MD™ system?

SCOUT MD™ is an advanced version of the original SCOUT system, providing enhanced tumor margin mapping with its specialized reflector shapes and radar signals.

How does Merit Medical support breast cancer patients?

Merit Medical is committed to supporting breast cancer patients through innovative products like SCOUT, continual education, and advocacy during Breast Cancer Awareness Month and beyond.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 9

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 11

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 12

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 7

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 12

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 7

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 8

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 11

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 6

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors in Light & Wonder, Inc. Urged to Act on Rights

Updated Category News Views 154

Light & Wonder, Inc. Investor Rights and Action Steps In a recent development, the Rosen Law Firm has taken the initiative to investigate potential securities claims for shareholders of Light & Wonder, Inc. If you have invested in Light & Wonder (NASDAQ: LNW), it is crucial to be informed about the ongoing legal matters that could impact your investments. Understanding...

Continue Reading
Exciting New Roaming Trails RV Community Launch in Texas

Updated Category News Views 170

Exciting New Roaming Trails RV Community Launch in Texas New gated RV destination brings elevated long-term stays to the Fort Worth metro area Provident is thrilled to unveil the grand opening of Roaming Trails RV Retreat, a new gated RV community located just south of Fort Worth. Set to commence operations on November 1, this marks Provident's first entry into the...

Continue Reading
Innovative Device Enhances At-Home Medical Exam Experience

Updated Category News Views 258

Revolutionizing Self-Exams with Innovative Design In today's fast-paced world, health awareness is more crucial than ever. Individuals often seek ways to monitor their health conveniently from the comfort of their home. Recognizing this need, an inventive mind has developed a unique device aimed at simplifying personal health examinations. The MEDICAL EXAM WAIST BAND...

Continue Reading
Emerita Resources Outlines Strategic Response to Aznalcollar Project Developments

Updated Category News Views 179

Emerita Resources Addresses New Developments in Aznalcollar Project Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) recently commented on significant changes regarding the Aznalcollar project in Spain. The Ministry of Energy and Mines announced that they have granted an exploitation license to Minera Los Frailes (MLF) to advance the project, but there are...

Continue Reading
Arvinas Unveils Promising Data for Its Cancer Treatment ARV-393

Updated Category News Views 219

Exciting Advances in Cancer Treatment by Arvinas Arvinas, Inc. (Nasdaq: ARVN), a groundbreaking biotechnology company focused on novel drug development through targeted protein degradation, has exciting news for the cancer research community. The company recently announced that promising preclinical combination data for its investigational drug ARV-393 will be showcased...

Continue Reading